Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
Authors
Daisuke Takahari
Gastroenterological Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto City, Tokyo, Japan
Daisuke Takahari , Akihito Kawazoe , Nozomu Machida , Keiko Minashi , Yukinori Yamagata , Hiroki Hara , Takeshi Omori , Manabu Yamamoto , Hisateru Yasui , Izuma Nakayama , Takanobu Yamada , Masayuki Kano , Takaki Yoshikawa , Masashi Wakabayashi , Yu Komura , Akihiro Sato , Takeshi Kuwata , Motohiro Kojima , Takahiro Kinoshita , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05034887
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 309)
DOI
10.1200/JCO.2024.42.3_suppl.309
Abstract #
309
Poster Bd #
E9
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).
First Author: Yelena Y. Janjigian
Poster
2024 ASCO Genitourinary Cancers Symposium
WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
First Author: Yige Bao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
First Author: Zhi Peng
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).
First Author: Campbell SD Roxburgh